Medication Treatment for Coccyx Injury
For acute coccyx injury, start with non-COX-2 specific NSAIDs (ibuprofen 400-600mg or naproxen) as first-line therapy, reserving opioids for severe pain unresponsive to NSAIDs, and consider corticosteroid injection if pain persists beyond conservative management.
First-Line Oral Analgesics
NSAIDs are superior to codeine-acetaminophen combinations for mild-to-moderate acute pain 1. The evidence strongly favors non-specific NSAIDs:
- Ibuprofen and naproxen have a number needed to treat (NNT) of 2.7 compared to 4.4 for codeine-acetaminophen 1
- NSAIDs provide longer time to re-medication with a safer side effect profile 1
- They avoid the CNS-depressing effects of codeine and the genetic variability in codeine metabolism (CYP2D6 polymorphism) 1
COX-2 specific NSAIDs (celecoxib 400mg) are also effective with an NNT of 2.5 and average time to re-medication of 8.4 hours 1. However, use COX-2 inhibitors cautiously in patients with cardiovascular disease risk, as they increase risk for myocardial infarction, stroke, heart failure, and hypertension 2. Use the lowest dose for the shortest duration necessary 2.
Important Caveat for Aspirin Users
If the patient takes low-dose aspirin for cardioprotection, ibuprofen interferes with aspirin's antiplatelet effect 2. Timing is critical:
- Take ibuprofen at least 30 minutes after immediate-release aspirin, or
- Take ibuprofen at least 8 hours before aspirin 2
Opioid Therapy for Severe Pain
When NSAIDs are insufficient for severe acute pain:
Oral opioids: Oxycodone-acetaminophen is marginally superior to codeine-acetaminophen 1
Intravenous opioids (if hospitalized):
- Hydromorphone (0.015 mg/kg IV) is comparable and potentially superior to morphine (0.1 mg/kg IV) 1
- Hydromorphone has quicker onset, less risk of dose stacking, and physicians may be more likely to adequately dose 1.5mg hydromorphone versus 10mg morphine 1
- Fentanyl (1 mcg/kg, then ~30 mcg every 5 minutes) is an alternative with shorter onset and higher potency 1
Interventional Treatments for Persistent Pain
When oral medications fail after conservative management:
Corticosteroid injection is the primary interventional option 3, 4, 5:
- Triamcinolone 20mg is superior to betamethasone 6mg for both early and long-term success 3
- Early success (pain-free at 3-4 months): 9% overall, significantly better with triamcinolone (OR 5.5) 3
- Long-term success: 15% after one injection, rising to 29% after a second injection 3
- Patients with symptoms <6 months respond significantly better (OR 3.0) than those with chronic pain 3, 4
- Fluoroscopically guided injections show that acute pain (<6 months) predicts relief, while chronic pain (>6 months) shows minimal response 4
Alternative interventional options 5, 6:
- Ganglion impar blockade
- Coccygeal nerve block (newer technique, US-guided, no radiation exposure) 6
- Pulsed radiofrequency therapy 7
Adjunctive Medication
Intranasal calcitonin may be considered specifically for acute coccyx fractures, though evidence is limited to small case series 8. It has been used for acute vertebral fracture pain and may accelerate healing 8.
Treatment Algorithm by Pain Duration
Acute pain (<6 months):
- NSAIDs (ibuprofen/naproxen) first-line
- Add or switch to oxycodone-acetaminophen if inadequate
- Consider corticosteroid injection if conservative measures fail after 4-6 weeks
Chronic pain (>6 months):
- NSAIDs for baseline management
- Corticosteroid injection has lower success but still worth attempting 3
- Consider ganglion impar block or coccygeal nerve block 6
- Multimodal pain assessment indicated due to chronification risk 9
Critical Pitfalls
- Do not use long-term NSAIDs or COX-2 inhibitors without physician consultation due to cardiovascular risks 2
- Screen for cardiovascular disease before prescribing COX-2 inhibitors 2
- Check aspirin use before prescribing ibuprofen to avoid negating cardioprotection 2
- Corticosteroid injections work best early - don't delay intervention in refractory acute cases 3, 4
- Avoid codeine-based medications as first-line due to inferior efficacy and genetic variability 1